Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Salahuddin M, Karanth S, Ocazionez D, Estrada-Y-Martin RM, Cherian SV. Clinical characteristics and etiologies of miliary nodules in the US: a single center study. Am J Med. 2019 Jun;132(6):767-9. doi: 10.1016/j.amjmed.2018.12.030
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Marin C, Ma CS, Zint K, Elsaesser A, Baretls DB, Lip GY. Antithrombotic treatment patterns in 10,871 patients with newly diagnosed non-valvular atrial fibrillation: the GLORIA-AF Registry Program, Phase II. Am J Med. 2015 Dec;128(12):1303-1313. doi: 10.1016/j.amjmed.2015.07.013
Bowater RJ, Hartley LC, Lilford RJ. Are cardiovascular trial results systematically different between North America and Europe? A study based on intra-meta-analysis comparisons. Arch Cardiovasc Dis. 2015 Jan;108(1):23-38. doi: 10.1016/j.acvd.2014.03.005
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.
Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992 Nov 1;93(5):513-9.
Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med. 1991 Oct 1;91(4):345-53.